Key statistics
As of last trade Alnylam Pharmaceuticals Inc (DUL:BER) traded at 238.20, -14.87% below its 52-week high of 279.80, set on Oct 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 235.80 |
---|---|
High | 238.20 |
Low | 235.50 |
Bid | 235.40 |
Offer | 240.80 |
Previous close | 235.00 |
Average volume | 63.56 |
---|---|
Shares outstanding | 128.98m |
Free float | 128.44m |
P/E (TTM) | -- |
Market cap | 31.83bn USD |
EPS (TTM) | -2.62 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 13:10 GMT.
More ▼
Press releases
- Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
- Alnylam to Webcast Presentations at Upcoming November Investor Conferences
- Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
- Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024
- Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results
- Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
- Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
- Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
- Alnylam to Webcast TTR Investor Day
- Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
More ▼